

**IL13 Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13737b****Specification****IL13 Antibody (C-term) Blocking peptide -  
Product Information**Primary Accession [P35225](#)**IL13 Antibody (C-term) Blocking peptide -  
Additional Information****Gene ID** 3596**Other Names**

Interleukin-13, IL-13, IL13, NC30

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13737b was selected from the C-term region of IL13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**IL13 Antibody (C-term) Blocking peptide - Protein  
Information****Name** IL13**Synonyms** NC30**Function**

Cytokine (PubMed:&lt;a href="http://www.uni

**IL13 Antibody (C-term) Blocking peptide -  
Background**

This gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. This cytokine is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4. [provided by RefSeq].

**IL13 Antibody (C-term) Blocking peptide -  
References**

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Shi, X., et al. Anat Rec (Hoboken) 293(9):1470-1476(2010) Beckers, M.M., et al. Eur. J. Intern. Med. 21(4):289-292(2010) Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press : Zhao, M., et al. J. Biomed. Biotechnol. 2010, 931018 (2010) :

prot.org/citations/8096327"  
target="\_blank">8096327</a>,  
PubMed:<a href="http://www.uniprot.org/ci  
tations/8097324"  
target="\_blank">8097324</a>). Inhibits  
inflammatory cytokine production  
(PubMed:<a href="http://www.uniprot.org/c  
itations/8096327"  
target="\_blank">8096327</a>).  
Synergizes with IL2 in regulating  
interferon-gamma synthesis (PubMed:<a hr  
ef="http://www.uniprot.org/citations/80963  
27" target="\_blank">8096327</a>). May  
be critical in regulating inflammatory and  
immune responses (PubMed:<a href="http:  
//www.uniprot.org/citations/8096327"  
target="\_blank">8096327</a>,  
PubMed:<a href="http://www.uniprot.org/ci  
tations/8097324"  
target="\_blank">8097324</a>). Positively  
regulates IL31RA expression in  
macrophages (By similarity).

#### **Cellular Location**

Secreted.

#### **IL13 Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you  
may find useful for product applications.

- [Blocking Peptides](#)